IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v496y2013i7446d10.1038_nature12053.html
   My bibliography  Save this article

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Author

Listed:
  • Hua-Xin Liao

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Rebecca Lynch

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Tongqing Zhou

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Feng Gao

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • S. Munir Alam

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Scott D. Boyd

    (Stanford University)

  • Andrew Z. Fire

    (Stanford University)

  • Krishna M. Roskin

    (Stanford University)

  • Chaim A. Schramm

    (Columbia University)

  • Zhenhai Zhang

    (Columbia University)

  • Jiang Zhu

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Lawrence Shapiro

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Columbia University)

  • James C. Mullikin

    (NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health)

  • S. Gnanakaran

    (Los Alamos National Laboratory)

  • Peter Hraber

    (Los Alamos National Laboratory)

  • Kevin Wiehe

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Garnett Kelsoe

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Guang Yang

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Shi-Mao Xia

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • David C. Montefiori

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Robert Parks

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Krissey E. Lloyd

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Richard M. Scearce

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Kelly A. Soderberg

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Myron Cohen

    (Epidemiology and Microbiology and Immunology, University of North Carolina)

  • Gift Kamanga

    (University of North Carolina Project, Kamuzu Central Hospital)

  • Mark K. Louder

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Lillian M. Tran

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Yue Chen

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Fangping Cai

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Sheri Chen

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

  • Stephanie Moquin

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Xiulian Du

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • M. Gordon Joyce

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Sanjay Srivatsan

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Baoshan Zhang

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Anqi Zheng

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • George M. Shaw

    (Perelman School of Medicine, University of Pennsylvania)

  • Beatrice H. Hahn

    (Perelman School of Medicine, University of Pennsylvania)

  • Thomas B. Kepler

    (Boston University)

  • Bette T. M. Korber

    (Los Alamos National Laboratory)

  • Peter D. Kwong

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • John R. Mascola

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Barton F. Haynes

    (Duke University Human Vaccine Institute, Duke University School of Medicine
    Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery)

Abstract

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.

Suggested Citation

  • Hua-Xin Liao & Rebecca Lynch & Tongqing Zhou & Feng Gao & S. Munir Alam & Scott D. Boyd & Andrew Z. Fire & Krishna M. Roskin & Chaim A. Schramm & Zhenhai Zhang & Jiang Zhu & Lawrence Shapiro & James C, 2013. "Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus," Nature, Nature, vol. 496(7446), pages 469-476, April.
    • Handle: RePEc:nat:nature:v:496:y:2013:i:7446:d:10.1038_nature12053
    DOI: 10.1038/nature12053
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature12053
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature12053?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mathilde Foglierini & Pauline Nortier & Rachel Schelling & Rahel R. Winiger & Philippe Jacquet & Sijy O’Dell & Davide Demurtas & Maxmillian Mpina & Omar Lweno & Yannick D. Muller & Constantinos Petrov, 2024. "RAIN: machine learning-based identification for HIV-1 bNAbs," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    2. Annemart Koornneef & Kanika Vanshylla & Gijs Hardenberg & Lucy Rutten & Nika M. Strokappe & Jeroen Tolboom & Jessica Vreugdenhil & Karin Feddes-de Boer & Aditya Perkasa & Sven Blokland & Judith A. Bur, 2024. "CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    3. Christoph Kreer & Cosimo Lupo & Meryem S. Ercanoglu & Lutz Gieselmann & Natanael Spisak & Jan Grossbach & Maike Schlotz & Philipp Schommers & Henning Gruell & Leona Dold & Andreas Beyer & Armita Nourm, 2023. "Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    4. Kim-Marie A. Dam & Christopher O. Barnes & Harry B. Gristick & Till Schoofs & Priyanthi N. P. Gnanapragasam & Michel C. Nussenzweig & Pamela J. Bjorkman, 2022. "HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    5. Rory Henderson & Ye Zhou & Victoria Stalls & Kevin Wiehe & Kevin O. Saunders & Kshitij Wagh & Kara Anasti & Maggie Barr & Robert Parks & S. Munir Alam & Bette Korber & Barton F. Haynes & Alberto Barte, 2023. "Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    6. Shixia Wang & Kun-Wei Chan & Danlan Wei & Xiuwen Ma & Shuying Liu & Guangnan Hu & Saeyoung Park & Ruimin Pan & Ying Gu & Alexandra F. Nazzari & Adam S. Olia & Kai Xu & Bob C. Lin & Mark K. Louder & Kr, 2024. "Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    7. Li Chen & Mengmeng Sun & Huajun Zhang & Xinghai Zhang & Yanfeng Yao & Ming Li & Kangyin Li & Pengfei Fan & Haiwei Zhang & Ye Qin & Zhe Zhang & Entao Li & Zhen Chen & Wuxiang Guan & Shanshan Li & Chang, 2024. "Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains," Nature Communications, Nature, vol. 15(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:496:y:2013:i:7446:d:10.1038_nature12053. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.